ProQR Therapeutics N.V. (PRQR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1 | 1 | 4 | 7 | 19 | 15 | 19 | 17 |
| Operating profit | €m | -42 | -43 | ||||||
| Net profit | €m | -47 | -61 | -64 | -28 | -28 | -41 | -42 | -43 |
| EPS reported | € | -0.38 | -0.40 | ||||||
| Operating cashflow per share | € | -0.50 | -0.45 | ||||||
| Capex per share | € | 0.01 | 0.01 | ||||||
| FCF per share | € | -0.51 | -0.46 | ||||||
| Free cash flow | €m | -54 | -50 | ||||||
| Net debt | €m | -103 | -104 | ||||||
| Book value equity | €m | 58 | 79 | ||||||
| Book value per share | € | 0.55 | 0.72 | ||||||
| Number of shares | m | 105.33 | 109.96 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.12 | 2.28 | ||||||
| P/S LTM | x | 11.85 | 9.75 | ||||||
| P/FCF LTM | x | -3.37 | -3.60 | ||||||
| EV/EBITDA LTM | x | -2.40 | -2.36 | ||||||
| EV/Sales LTM | x | 5.82 | 3.82 | ||||||
| Earnings Yield LTM | % | -22.37% | -23.24% | ||||||
| FCF Yield | % | -29.71% | -27.77% | ||||||
| Quality | |||||||||
| ROE | % | -69.88% | -68.44% | ||||||
| ROIC | % | -42.35% | -41.91% | ||||||
| Operating margin | % | -2.76% | -2.33% | ||||||
| Gross margin | % | +83.01% | +92.33% | ||||||
| FCF/Sales | % | -352.21% | -270.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -19.18% | -1.75% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.27 | -3.81 | ||||||
| Net Debt/EBITDA | x | 2.49 | 2.76 | ||||||
| EBIT/Net interest | x | -48.66 | 0.00 | ||||||
| Net debt/market cap | % | +2.88% | +2.57% | ||||||
| Net debt/Equity | x | -1.78 | -1.31 | ||||||
| Gross debt/equity | x | 0.28 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free